HAIMBIO
HaimBio is a drug development company. Their flagship product, Starvanip, is a metabolism-based cancer therapy that kills cancer cells by starving them of metabolic energy. Starvanip inhibits cancer cell growth and induces apoptosis -- the death of cancer cells. It does this by inhibiting the energy source of cancer cells, dramatically reducing side effects such as harm to normal cells and reducing the toxicity of current anticancer therapies. The drug will also improve the rate of response and target a wider range of cancers. Tests have demonstrated efficacy with 12 types of cancer, as well as significant reductions of tumor sizes and increases of cancer cell death with almost no death of normal cells.
HAIMBIO
Social Links:
Industry:
Biotechnology Medical
Founded:
2011-09-26
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.en.haimbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3 M KRW
Technology used in webpage:
SPF ASP.NET IIS IIS 10 Japanese Yen GlobalSign Classic ASP Naver Analytics
Similar Organizations
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.en.haimbio.com
- Host name: 211.47.74.128
- IP address: 211.47.74.128
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "HaimBio"
Articles of Association of AIM Vaccine Co., Ltd. - AIM Bio
GENERAL PROVISIONS Article 1 To safeguard the legitimate rights and interests of AIM …See details»
AIM Vaccine - Crunchbase Company Profile & Funding
AIM Vaccine is a full-chain vaccine corporation in China with businesses covering the whole industrial chain.See details»
AIM Vaccine Co., Ltd – DCVMN
AIM Vaccine Co., Ltd. (referred to as “AIM”), committing to develop and manufacture top quality vaccines to safeguard the health of the world, is a major vaccine company in China, which covers the full value chain from research …See details»
Contact_AIM Bio
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd. 26F，Building T6, Dazu Square, Economic and Technological Development Zone, Beijing, China [email protected]；International …See details»
AIM Vaccine Co., Ltd. 艾美疫 - en.aimbio.com
AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 Hong Kong Exchanges and Clearing Limited and …See details»
职业发展_艾美疫苗 - AIM Bio
艾美疫苗是中国大型全产业链民营疫苗集团，业务涵盖从研发到制造、再到商业化的整个行业价值链，2020年取得了约60百万剂的批签发量，实现向中国31个省、自治区及直辖市销售疫苗产 …See details»
Aimbio - LinkedIn
Aimbio is a leading manufacturer of high-quality, automated PCR systems and reagents. Our …See details»
全面接入DeepSeek大模型，实现「AI+疫苗智能企业」战略升级_公 …
作为中国头部的疫苗企业，本集团积极响应国家「AI+」产业发展战略，全面部署接 …See details»
公司动态_新闻中心_艾美疫苗 - aimbio.com
本集团按照既定公司战略积极推进疫苗产品管线的开发，利用mRNA技术平台优势，通过持续的技术创新，快速推进mRNA疫苗系列产品的研发，mRNA呼吸道合胞病毒疫苗已于近日获得美国食品和药品监督管理局 (FDA)临床试验许可。这也 …See details»
Rising Star of International First-line Vaccine AIM …
Another success of AIM Vaccine Co., Ltd.—its wholly-owned subsidiary AIM Vacin obtained the Notice of Approval for Drug Clinical Trial for its ACYW135 Meningococcus Conjugate Vaccine (MCV4) from the National Medical …See details»
Hangzhou Zhunxin Biotechnology …
We have two separate product lines in Europe. Fluorescence Immunoassay and automated PCR system which requires minimal training.See details»
长期主义效应显现，艾美疫苗3款重磅疫苗加速上市，2款mRNA疫 …
上半年，艾美疫苗按照既定战略积极推进疫苗产品管线的开发，通过持续的技术创新，快速推进 …See details»
Company News_News_AIM Bio
The clinical trial approval for the human diploid rabies vaccine developed by the Group has …See details»
重组乙型肝炎疫苗 (艾美汉信疫苗（大连）有限公司) (Recombinant …
Estudio con pacientes en prediálisis y diálisis renal para evaluar la seguridad, tolerabilidad e …See details»
mail.aimbio.com - 艾美疫苗股份有限公司
自动登录登录See details»
Media Reports_News_AIM Bio
Vaccine leader Amy is in the midst of a year of intensive product declaration, and good news …See details»
公告 | 迭代工艺高效价人二倍体狂犬疫苗申报临床_公司动态_新闻 …
艾美疫苗研发的迭代工艺高效价人二倍体狂犬疫苗已于近日向中国药品监督管理局药品审评中心 …See details»
Establishing Canada’s first large-scale bioinnovation centre
2 days ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot …See details»
DTP vaccine combination_Products_Upcoming Products_R&D_AIM …
DTP vaccine combination In such vaccine combination, DTap is the leading product in China’s …See details»
新质生产力时代千帆竞技 艾美疫苗把握创新高点 投资价值凸显_媒 …
有统计根据欧美成熟市场的经验测算，答案是8~12年，而这还仅仅是平均水平。回望过去，还 …See details»